Net sales declined -5.39%  to  Rs. 2311.95 million from Rs. 2443.61 millions.The Net Loss for the quarter ended December 2019 is Rs. -203.68 millions as compared to Net Profit of Rs. 63.20 millions of corresponding quarter ended December 2018Operating profit Margin for the quarter ended December 2019 slipped to -26.93% as compared to 79.35% of corresponding quarter ended December 2018 (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 2311.95 2443.61 -5.39 6888.13 6906.57 -0.27 9677.39 6664.70 45.20 Other Income 230.09 272.90 -15.69 800.42 789.84 1.34 1015.42 628.86 61.47 PBIDT -26.93 79.35 -133.94 4.07 229.98 -98.23 407.50 -733.42 -155.56 Interest 4.18 1.27 229.13 6.96 2.06 237.86 6.17 31.67 -80.52 PBDT -31.11 78.08 -139.84 -2.89 227.92 -101.27 401.33 -765.09 -152.46 Depreciation 172.57 168.28 2.55 519.77 439.90 18.16 617.13 450.41 37.02 PBT -203.68 -90.20 125.81 -522.66 -211.98 146.56 -215.80 -1215.50 -82.25 TAX 0.00 -153.40 0.00 -74.98 -245.47 -69.45 -286.23 -1.40 20345.00 Deferred Tax 0.00 -140.95 0.00 -74.98 -233.02 -67.82 -273.78 125.79 -317.65 PAT -203.68 63.20 -422.28 -447.68 33.49 -1436.76 70.43 -1214.10 -105.80 Equity 140.81 140.77 0.03 140.81 140.77 0.03 140.77 140.67 0.07 PBIDTM(%) -1.16 3.25 -135.87 0.06 3.33 -98.23 4.21 -11.00 -138.26

The sales declined to Rs. 2250.97 millions for the September 2019 quarter as compared to Rs. 2449.42 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2019 is Rs. -248.64 millions as compared to Net Profit of Rs. 176.82 millions of corresponding quarter ended September 2018Operating profit Margin for the quarter ended September 2019 slipped to -67.69% as compared to 344.00% of corresponding quarter ended September 2018 (Rs. in Million) Quarter ended Year to Date Year ended 201909 201809 % Var 201909 201809 % Var 201903 201803 % Var Sales 2250.97 2449.42 -8.10 4576.18 4462.96 2.54 9677.39 6664.70 45.20 Other Income 290.49 325.58 -10.78 570.33 516.94 10.33 1015.42 628.86 61.47 PBIDT -67.69 344.00 -119.68 31.00 150.63 -79.42 407.50 -733.42 -155.56 Interest 2.31 0.67 244.78 2.78 0.79 251.90 6.17 31.67 -80.52 PBDT -70.00 343.33 -120.39 28.22 149.84 -81.17 401.33 -765.09 -152.46 Depreciation 178.64 148.13 20.60 347.20 271.62 27.83 617.13 450.41 37.02 PBT -248.64 195.20 -227.38 -318.98 -121.78 161.93 -215.80 -1215.50 -82.25 TAX 0.00 18.38 0.00 -74.98 -92.07 -18.56 -286.23 -1.40 20345.00 Deferred Tax 0.00 18.38 0.00 -74.98 -92.07 -18.56 -273.78 125.79 -317.65 PAT -248.64 176.82 -240.62 -244.00 -29.71 721.27 70.43 -1214.10 -105.80 Equity 140.81 140.69 0.09 140.81 140.69 0.09 140.77 140.67 0.07 PBIDTM(%) -3.01 14.04 -121.41 0.68 3.38 -79.93 4.21 -11.00 -138.26

Unichem Laboratories is currently trading at Rs. 175.80, up by 5.85 points or 3.44% from its previous closing of Rs. 169.95 on the BSE.The scrip opened at Rs. 171.10 and has touched a high and low of Rs. 178.65 and Rs. 169.80 respectively. So far 4621 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 239.75 on 10-Sep-2018 and a 52 week low of Rs. 158.35 on 31-Jul-2019.Last one week high and low of the scrip stood at Rs. 178.65 and Rs. 169.40 respectively. The current market cap of the company is Rs. 1195.49 crore.The promoters holding in the company stood at 50.62%, while Institutions and Non-Institutions held 9.49% and 39.88% respectively.United States Food and Drug Administration (USFDA) has conducted inspection at the Unichem Laboratories’ Pithampur, Active Pharmaceutical Ingredients (APIs) facility from September 02, 2019 to September 05, 2019. The inspection was a post approval inspection and successfully concluded without any USFDA form 483 issued.Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 179.05, up by 1.05 points or 0.59% from its previous closing of Rs. 178.00 on the BSE.The scrip opened at Rs. 178.00 and has touched a high and low of Rs. 180.80 and Rs. 174.35 respectively. So far 3603 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 239.75 on 10-Sep-2018 and a 52 week low of Rs. 158.35 on 31-Jul-2019.Last one week high and low of the scrip stood at Rs. 180.80 and Rs. 163.75 respectively. The current market cap of the company is Rs. 1256.74 crore.The promoters holding in the company stood at 50.62%, while Institutions and Non-Institutions held 9.49% and 39.88% respectively.Unichem Laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Unichem`s Tramadol Hydrochloride Tablets USP, 50 mg. to market a generic version of Ultram Tablets, 50 mg, of Janssen Pharmaceuticals, Inc. which are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The Product will be commercialized from the company’s Ghaziabad plant. Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 186.80, up by 0.45 points or 0.24% from its previous closing of Rs. 186.35 on the BSE.The scrip opened at Rs. 186.20 and has touched a high and low of Rs. 189.95 and Rs. 185.50 respectively. So far 3519 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 288.40 on 08-May-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 192.95 and Rs. 185.50 respectively. The current market cap of the company is Rs. 1314.76 crore.The promoters holding in the company stood at 50.64%, while Institutions and Non-Institutions held 9.41% and 39.95% respectively.Unichem Laboratories has received tentative ANDA approval from the United States Food and Drug Administration (USFDA) for Unichem`s Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 5 mg/120 mg (OTC) to market a generic version of Johnson and Johnson Consumer Inc`s Zyrtec-D 12 Hour (Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride, 5mg/120 mg) Extended Tablets.The product will be commercialized from Unichem’s Goa Plant on receipt of final approval. Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 202.00, up by 6.85 points or 3.51% from its previous closing of Rs. 195.15 on the BSE.The scrip opened at Rs. 199.45 and has touched a high and low of Rs. 295.00 and Rs. 199.45 respectively. So far 4121 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 295.00 on 28-Mar-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 204.40 and Rs. 188.40 respectively. The current market cap of the company is Rs. 1373.53 crore.The promoters holding in the company stood at 50.64%, while Institutions and Non-Institutions held 8.38% and 40.98% respectively.Unichem Laboratories has received final Approval for its ANDA, Tadalafil Tablets, 2.5 mg, 5 mg 10 mg and 20 mg from the United States Food and Drug Administration (USFDA) for a generic version of ELI LILLY`s Cialis, 2.5 mg, 5 mg, 10 mg and 20 mg.The company`s Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH) and ED and the signs and symptoms of BPH (EDIBPH).Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

The turnover soared 52.77% to Rs. 2447.62 millions for the December 2018 quarter as compared to Rs. 1602.14 millions during the corresponding quarter last year.The Total Profit for the quarter ended December 2018 of Rs. 63.21 millions grew from Rs.-579.67 millions Operating profit Margin for the quarter ended December 2018 improved to 79.36% as compared to -483.68% of corresponding quarter ended December 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 2447.62 1602.14 52.77 6921.07 4646.24 48.96 6697.31 5770.23 16.07 Other Income 275.57 56.07 391.47 794.56 174.56 355.18 628.86 71.93 774.27 PBIDT 79.36 -483.68 -116.41 229.97 -927.89 -124.78 -733.42 -508.26 44.30 Interest 1.27 9.30 -86.34 2.06 26.46 -92.21 31.67 19.98 58.51 PBDT 78.09 -492.98 -115.84 227.91 -954.35 -123.88 -765.09 -528.24 44.84 Depreciation 168.28 115.27 45.99 439.90 322.88 36.24 450.41 394.11 14.29 PBT -90.19 -608.25 -85.17 -211.98 -1277.26 -83.40 -1215.50 -922.35 31.78 TAX -153.40 -28.58 436.74 -245.47 -35.12 598.95 -1.40 -167.04 -99.16 Deferred Tax -140.95 -90.14 56.37 -233.02 86.00 -370.95 125.79 -26.23 -579.57 PAT 63.21 -579.67 -110.90 33.49 -1242.11 -102.70 -1214.10 -755.31 60.74 Equity 140.77 181.87 -22.60 140.77 181.87 -22.60 140.67 181.75 -22.60 PBIDTM(%) 3.24 -30.19 -110.74 3.32 -19.97 -116.64 -10.95 -8.81 24.33

Unichem Laboratories is currently trading at Rs. 195.60, up by 3.50 points or 1.82% from its previous closing of Rs. 192.10 on the BSE.The scrip opened at Rs. 200.95 and has touched a high and low of Rs. 200.95 and Rs. 194.75 respectively. So far 10694 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 200.95 and Rs. 188.50 respectively. The current market cap of the company is Rs. 1379.51 crore.The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 10.22% and 39.11% respectively.Unichem Laboratories has received final ANDA approval for its Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Boehringer Ingelheim Pharmaceuticals Inc.`s Mirapexe Tablets, 0.125 mg. 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg. Pramipaxole Dihydrochloride Tablets are indicated for the treatment of Parkinson`s disease and moderate-to-severe primary Restless Legs Syndrome (RLS).Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 194.80, up by 3.55 points or 1.86% from its previous closing of Rs. 191.25 on the BSE.The scrip opened at Rs. 198.05 and has touched a high and low of Rs. 198.05 and Rs. 194.20 respectively. So far 12760 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 199.70 and Rs. 188.75 respectively. The current market cap of the company is Rs. 1367.55 crore.The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 10.22% and 39.11% respectively.Unichem Laboratories has received Tentative Approval for its Abbreviated New Drug Application (ANDA), Tadalafil Tablets, 2.5 mg, 5 mg 10 mg and 20 mg from the United States Food and Drug Administration (USFDA) for a generic version of ELI LILLY`s Cialis, 2.5 mg, 5 mg, 10 mg and 20 mg.The company`s Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED) and treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) and the treatment of ED and the signs and symptoms of BPH (ED/BPH).Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 217.00, up by 14.40 points or 7.11% from its previous closing of Rs. 202.60 on the BSE.The scrip opened at Rs. 223.00 and has touched a high and low of Rs. 224.55 and Rs. 215.70 respectively. So far 47214 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 224.55 and Rs. 201.10 respectively. The current market cap of the company is Rs. 1425.96 crore.The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 10.22% and 39.11% respectively.Unichem Laboratories has received Establishment Inspection Report (EIR) for the Post Marketing Adverse Drug Experience inspection conducted at Unichem Bhavan, Prabhat Esate in Mumbai by the US Food and Drug Administration (USFDA) from June 25, 2018 to June 29, 2018, indicating closure of inspection.Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Laboratories is currently trading at Rs. 221.00, up by 10.70 points or 5.09% from its previous closing of Rs. 210.30 on the BSE.The scrip opened at Rs. 210.95 and has touched a high and low of Rs. 227.00 and Rs. 210.00 respectively. So far 35878 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 227.00 and Rs. 203.00 respectively. The current market cap of the company is Rs. 1491.62 crore.The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 10.22% and 39.11% respectively.The company has reported a fall of 66.80% in its net profit at Rs 15.21 crore for second quarter ended September 30, 2018 as compared to Rs 45.82 crore for the same quarter in the previous year. However, total income of the company increased by 65.66% at Rs 278.50 crore for Q2FY19 as compared Rs 168.12 crore for the corresponding quarter previous year.Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

The turnover is pegged at Rs. 2459.17 millions for the September 2018 quarter. The mentioned figure indicates a rise of about 51.14% as against Rs. 1627.11 millions during the year-ago period.The Total Profit for the quarter ended September 2018 of Rs. 176.81 millions grew from Rs.-330.81 millions Operating profit Margin for the quarter ended September 2018 improved to 343.99% as compared to -172.57% of corresponding quarter ended September 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 2459.17 1627.11 51.14 4473.45 3044.10 46.95 6697.31 5770.23 16.07 Other Income 325.83 54.11 502.16 518.99 118.49 338.00 628.86 71.93 774.27 PBIDT 343.99 -172.57 -299.33 150.61 -444.21 -133.91 -733.42 -508.26 44.30 Interest 0.67 10.56 -93.66 0.79 17.16 -95.40 31.67 19.98 58.51 PBDT 343.32 -183.13 -287.47 149.82 -461.37 -132.47 -765.09 -528.24 44.84 Depreciation 148.13 108.11 37.02 271.62 207.61 30.83 450.41 394.11 14.29 PBT 195.19 -291.26 -167.02 -121.79 -669.01 -81.80 -1215.50 -922.35 31.78 TAX 18.38 39.55 -53.53 -92.07 -6.54 1307.80 -1.40 -167.04 -99.16 Deferred Tax 18.38 98.64 -81.37 -92.07 176.14 -152.27 125.79 -26.23 -579.57 PAT 176.81 -330.81 -153.45 -29.72 -662.44 -95.51 -1214.10 -755.31 60.74 Equity 140.69 181.84 -22.63 140.69 181.84 -22.63 140.67 181.75 -22.60 PBIDTM(%) 13.99 -10.61 -231.87 3.37 -14.59 -123.07 -10.95 -8.81 24.33